
ABOUT CATALENT
Catalyst + Talent. Our name combines these ideas. As the world’s #1 drug development, delivery and supply partner with over 80 years of experience, we are the catalyst for your success. We have helped thousands of innovators by optimizing and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products utilizing our superior and innovative drug delivery technologies to improve their value to patients and consumers.
Catalent is a vibrant growing community of 8,500 global employees with the passion to unlock the potential of your product. Founded in 2007 as Catalent, our legacy of drug development goes much deeper, incorporating the inventions and innovations which have transformed the pharmaceutical industry. On July 30, 2014 Catalent announced its initial public offering and became a publicly traded on the New York Stock Exchange under the ticker symbol CTLT.
From early development to clinical supply and commercial manufacturing, our 30+ global site teams support you through all phases of development, delivery, and supply, accelerating your product’s path to market in segments such as pharmaceuticals, biologics, consumer health and beauty, and animal health utilizing our superior drug delivery technologies to improve therapeutic and product value to patients and consumers.
Whether you seek a single tailored solution or partnership through your product’s entire life cycle, we put our experience, expertise, and passion to work for you in unlocking the potential of your product.
ORAL CONTENT
CONTACT INFORMATION
Catalent
14 Schoolhouse Road
Somerset, NJ 08873
UNITED STATES
Phone: 877-587-1835
BIOLOGICS CONTENT
- Getting Your Biologic To Clinic Faster & More Efficiently
- Secondary Packaging Strategies For Commercial Launch Of A Biologic
- Process Development: Ensuring A Consistent, High-Quality Biologic
- Rapid Global Characterization Of Ig G1 Following Oxidative Stress
- High-Throughput Preformulation Development Platform For Biologics
- Analytical Quality By Design Using Design Of Experiments
- Strategies To Achieve Successful Approval & Launch
- Standardizing Process Characterization And Late Phase Development
- Characterization Of A Therapeutic mAb, Associated Antigen-Binding Fragments
- Intensified Fed-Batch Process Using N-1 Perfusion And ambr 15
- Ensuring Success In Early Biopharmaceutical Formulation Development
- Solution To Ensure Quantity And Quality Of The Excipient Polysorbate-80 In Drug Formulations
- Comparing Batch Versus Continuous Modes
- ICP-MS Analysis Of Multiple Trace Elements In Industrial Cell Lines
- A Novel Purification Tool's Effects On HCP Reduction, Turbidity
- High-Throughput Formulation Dev. For High-Concentration mAbs
CELL AND GENE CONTENT
- The Journey Into Cell & Gene Therapy
- Radiance Label-Free Monitoring Of AAV Transfection In HEK293 Cells
- Are Real-Time Gene Therapy Test Results Possible?
- Unprecedented Growth — And Challenges — In Gene Therapy
- Manufacturing Strategies To Industrialize Autologous Cell Therapies
- The Raw Material Hurdle: Plasmids For Viral Vector-Based Gene Therapies
- Technology Integrators In Cell And Gene Therapy: Powering Innovation
- Preparing For The Commercial Scale Production Of Cell Therapies
- Integrated Solutions For Advanced Therapeutics
- Manufacturing Innovation Across New Modalities
- Practical, Innovative Solutions For AAV Development, Manufacturing
- Confronting Scalability With Autologous Therapies
- Overcoming Commercialization Challenges For Cell & Gene Therapies
- Navigating The Path To The Clinic And Beyond For Gene Therapies
- How To Commercially Scale T-Cell Allogeneic Therapies